Given the finding that peptide [SRSRY] inhibits cell migration by antagonizing FPR1 biologic activity, [SRSRY] may be considered as a potent and stable FPR1 inhibitor which may suggest the generation of new pharmacological treatments for diseases sustained by an excess of monocyte trafficking, such as chronic inflammatory diseases and cancer. This evidence concerns the gene FPR1 and cancer.